Table 2.

Spearman’s correlations between baseline characteristics and the eight dimensions and component summaries of the SF-36 in 252 patients with systemic lupus erythematosus

Disease characteristics	PF	RP	BP	GH	VT	SF	RE	MH	PCS	MCS
Age at assessment	−0.27****	−0.08	−0.18**	−0.05	−0.01	0.02	−0.07	0.15*	−0.24***	0.06
Body mass index	−0.25***	−0.12	−0,16*	−0.07	−0.11	−0.13	−0.15*	0.01	−0.18**	−0.05
Disease duration	0.14*	0.13	0.02	0.03	0.11	0.06	0.03	0.14*	0.12	0.02
SELENA-SLEDAI	−0.07	−0.27**	−0.22**	−0.09	−0.15*	−0.14*	−0.27**	−0.16*	−0.14*	−0.21***
PGA	−0.17**	−0.23***	−0.32****	−0.08	−0.13*	−0.13*	−0.19**	−0.16*	−0.21***	−0.14*
ESR	−0.26***	−0.24***	−0.23***	−0.11	−0.13	−0.15*	−0.21**	−0.14*	−0.23***	−0.14*
Haemoglobin	0.16*	0.19**	0.07	0.04	0.05	0.09	0.14**	0.01	0.14*	0.06
Serum albumin level	0.06	0.16*	0.12	0.01	−0.01	0.14	0.11	−0.04	0.12	0.02
Daily prednisone equivalent	−0.03	−0.16	−0.17	0.09	−0.01	−0.18*	−0.10	−0.09	−0.08	−0.10

ESR Erythrocyte sedimentation rate, PGA Physician’s global assessment, SELENA-SLEDAI Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score with the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA), SDI Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index, PF physical function, RP role physical, BP bodily pain, GH general health, VT vitality, SF social function, RE role emotional, MH mental health, PCS Physical Component Summary, MCS Mental Component Summary

*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001